Article Text

Download PDFPDF
Adding aripiprazole improves major depressive disorder following incomplete response to antidepressants alone

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Robert M Berman, MD

Bristol-Myers Squibb Co., 5 Research Parkway, Wallingford, CT 06492, USA;



How effective and safe is aripiprazole when added to antidepressants in people with major depressive disorder and a history of incomplete response?


362 adults with major depressive disorder (DSM-IV-TR) whose current episode had failed to show complete response to an 8-week trial of standard antidepressant plus adjunctive placebo. Incomplete response was defined as <50% reduction in 17-item Hamilton Rating Scale for Depression (HAM-D17) total score, HAM-D17 score ⩾14, and a Clinical Global Impressions-Improvement scale score ⩾3. Participants enrolled in the 8-week trial had to have HAM-D17 total score ⩾18, and a history of inadequate response (<50% reduction in Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (ATRQ)) to 1–3 adequate antidepressant treatments (>6 weeks using adequate dose as specified in the ATRQ) for their current depressive episode.


24 sites in the USA; June 2004 to April 2006.


Adjunctive aripiprazole (2–20 mg daily depending on antidepressant being …

View Full Text


  • Source of funding: Bristol-Myers Squibb Co and Otsuka Pharmaceutical Co, Ltd.


  • Competing interests: None declared.